Uncommon EGFR mutations in NSCLC, such as exon 20 insertions, are being targeted by new therapies like amivantamab, zipalertinib, and furmonertinib. Subcutaneous amivantamab, combined with lazertinib, ...
Results from the global phase III Harmoni trial presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC) showed a statistically significant ...
Thank you for waiting everybody. We will now start Daiichi Sankyo's WCLC 2025 highlights. This is Ken Asakura from Corporate Communications, and I will be the moderator today. First, about the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results